# Research Article

Prognostic determinants of anterior large vessel occlusion in acute stroke in elderly patients.

Takashi Mitsuhashi MD, Ph D.<sup>a</sup>, Kohsuke Teranishi MD, Ph D., <sup>b</sup> Joji Tokugawa MD, Ph D. <sup>a</sup>, Takumi Mitsuhashi MD., Ph D. <sup>a</sup>, Makoto Hishii MD, Ph D. <sup>a</sup>, Hidenori Oishi MD, Ph D. <sup>b,c</sup>

<sup>a</sup> Department of Neurosurgery/Juntendo University/Nerima Hospital, Tokyo, Japan

<sup>b</sup> Department of Neurosurgery/ Juntendo University/Tokyo, Japan

<sup>c</sup> Department of Neuroendovascular Therapy/ Juntendo University/Tokyo, Japan

Short Title: Prognostic Factors in Elderly Patients Undergoing Mechanical Thrombectomy

Corresponding Author:

Takashi Mitsuhashi

Department of Nerosurgery, Juntendo University Nerima Hospital

3-1-10 Takanodai, Nerima-ku, Tokyo, Japan

Tel: +81-3-5923-3111

E-mail: ta-kashi@wa2.so-net.ne.jp

Number of Tables: 4.

Number of Figures: none.

Word count: 3898

June. 3030

Keywords: Mechanical thrombectomy, Large vessel occlusion, elderly, prognosis

# 1 Abstract

- 2 Introduction.- Mechanical thrombectomy(MT) has been shown to be safety and
- 3 effectiveness for acute anterior circulation large vessel occlusion(LVO)of all ages, and
- 4 together with intravenous thrombolysis has become an standard treatment for acute stroke.
- 5 In an aging world, the effectiveness of MT for the elderly has not been fully demonstrated.
- 6 We investigated factors associated with prognosis in elderly patients undergoing MT in
- 7 Japanese practice, where the elderly are defined as those aged 80 years or older, in the
- 8 context of an ageing population.
- 9 **Method.** MT was performed in 59 cases of LVO of the anterior circulation. Primary outcome
- 10 evaluated functional outcome at three months. Parametric and/or non-parametric test and a
- binomial logistic regression model was performed to identify prognosis factors in elderly
- 12 patients.
- 13 **Results.** Overall, Of the 59 patients, 47.5% (28/59) achieved an mRS  $\leq$ 3 at 3 months.
- Mortality rate was 20.3% (12/59). Younger age(P=0.032), lower NIHSS on
- admission(P=0.00005), lower level of NT-proBNP on admission(P=0.041), lower level of D-
- dimer on admission(P=0.01), First Pass Effect (FPE) (P=0.024) and good
- recanalization (P=0.0025) were associated with favorable clinical outcome. In the binomial
- 18 logistic regression model, only lower NIHSS on admission was significantly associated with
- 19 good clinical outcome.
- 20 Conclusions. In the present study, not only were younger age, lower NIHSS on admission
- 21 and FPE already reported as prognostic factors for MT for LVO in the elderly, but also,
- 22 although not previously reported, lower levels of NT-proBNP on admission and lower level of
- 23 D-dimer on admission were considered as possible prognostic factors.

#### Introduction

25

- Several randomised controlled trials of mechanical thrombectomy (MT) for the treatment of
- acute anterior circulation large vessel occlusion (LVO) have demonstrated efficacy and safety
- 28 in all age groups. [1]
- 29 MT has become one of the standard treatments for acute ischemic stroke caused by LVO,
- 30 along with intravenous thrombolysis. Some guidelines recommended considering MT for
- occlusion of the M1 segment of the middle cerebral artery or internal carotid artery. [2,3] As
- Hendrix et al. also pointed out, although the guideline proved to be a class 1 recommendation
- for MT in patients over 80 years of age, several RCTs have excluded patients over 80 or 85
- years of age.[4]
- 35 On the other hand, it is recognized that life expectancy has increased worldwide in recent
- 36 years and that the risk of developing ischemic stroke is thought to increase as the number of
- older people increases and as they get older. Some previous studies have shown that people
- over 80 years of age have the highest incidence of acute ischemic stroke. [5]
- However, the evidence for MT in elderly patients with LVO is scarce and not explicitly stated
- 40 in the guidelines. Furthermore, Alawieh et al. point out that many of the previous conclusions
- regarding the efficacy and safety of MT in the elderly were based on single-arm, single-
- 42 institute studies, resulting in significant heterogeneity among studies and a lack of comparison
- with optimal medical management. [6]
- Previous studies on MT for LVO have highlighted advanced age as a strong predictor of
- unfavorable outcome after MT. [7,8]
- 46 Japan has the highest ageing rate in the world, and other developed countries are also
- 47 expected to become ageing societies.
- 48 The safety and efficacy of MT for LVO have been reported in octogenarians, nonagenarians,
- and elderly patients with LVO, including prognosis-related factors.
- 50 Factors contributing to outcome include successful reperfusion, first pass effect (FPE), low
- NIHSS score on admission, initial ASPECTS, time from onset to groin puncture, time from
- 52 groin puncture to recanalization, pre-existing functional deficits, and age over 80 years.
- 53 [6,9,10,11,12,13]

- Although, the HERMES meta-analysis showed that MT had beneficial effects in patients aged
- 80 years or older patients, the proportional of cases over 80 years of age was low. [1]
- Therefore, the current guidelines for the United States provide class 1 recommendation for
- 57 MT in patients aged 80 years or older. [14]
- Therefore, Zaidat et al. dichotomized patient age based on previous studies, using 80 years as
- 59 the cut-off point and defining elderly patients as those aged 80 years or older. In the TRACK
- registry, age  $\geq 80$  years was reported to be a prognostic factor and that the rate of patients with
- an mRS score 0 to 2 at 90 days decreased slightly with age.[15]
- 62 In addition, Meyer et al. pointed out that no substantial therapy recommendation for patients
- aged 90+ was derived from the recent landmark thrombectomy trials. [16]
- In the present study, we defined "elderly" as those over 80 years of age because, as mentioned
- above, many studies, including previous guidelines, often set the age at which a person is
- considered elderly at 80 years. Furthermore, since the average life expectancy of Japanese
- 67 men is in the early 80s and that of women in the mid 80s, we defined those aged 80 and over
- 68 as elderly.
- 69 Since many elderly patients have undergone MT for LVO in our medium-sized hospital in
- Japan, which has an aging population, we investigated the results of MT for LVO in elderly
- 71 patients and reviewed the prognostic factors. To identify factors associated with favorable
- outcome in patients who have underwent MT for LVO.

# 73 Materials and Methods

# 74 Patient selection

- 75 Consecutive 141 patients who underwent MT for anterior circulation LVO at our hospital
- between October 2015 and October 2021 were retrospectively reviewed. In this retrospective
- single-center study, the protocol was approved by the ethics committee of Juntendo
- 78 University Nerima Hospital.
- 79 The inclusion criteria of the present study were as follows; (1) acute ischemic stroke due to
- 80 LVO within the anterior circulation, including the internal carotid artery (ICA) or middle
- cerebral artery (MCA), with or without additional intravenous thrombolysis; (2) age at onset
- 82 is 80 years or older; (3) known admission National Institute of Health Stroke Scale

- 83 (NIHSS), Alberta Stroke Program Early CT Score (ASPECTS), and Diffusion-weighted
- imaging ASPECTS (DWI-ASPECTS) for patients who are eligible for magnetic resonance
- 85 imaging; (4) known values of the premorbid modified Rankin Scale (mRS) and mRS at 90
- 86 days after stroke.
- Data were collected on age at admission, sex, time of onset or last known well time, time of
- arrival at our institute, NIHSS at admission, blood collection data at admission (N-Terminal
- Pro-Brain Natriuretic Peptide (NT-proBNP) (pg/ml), D-dimer (µg/ml), Glycated hemoglobin
- 90 (HbA1c) (%)), time of recanalization, number of attempts, and angiographic recanalization
- 91 status as modified thrombolysis in cerebral infarction (mTICI).
- 92 In this study we defined a clinical outcome mRS 0-3 as favorable clinical outcome, for the
- 93 following reasons.
- 94 The mRS is a non-linear scale, a measure of Activity of Daily Life that focuses primarily on
- 95 mobility, and dichotomization of outcomes has been used in research studies. Many previous
- studies, including HERMES, have treated mRS0-2 as a good clinical outcome. [1] However,
- Wilson et al. pointed out that the lower inter-rater reliability in classifying patients as mRS2
- 98 and 3 or by the existence of subgroups within the mRS3 group. [17] In Addition, Rangraju et
- 99 al. described that the patients who achieved mRS3 were more similar to mRS2 than mRS4
- patients in terms of on functional disability and quality of life. [18]
- The majority of patients underwent MT under local anesthesia with the use of a stent-retriever
- and/or an aspiration catheter.

# **Study End Points**

103

106

- The primary neurological end point of this study was the rate of favourable clinical outcome
- defined as mRS  $\leq 3$  at 90-day follow up, adjusted for patient age.

# Statistical analysis

- 107 Variables were compared between two groups: mRS 0-3; favourable clinical outcome and 4-
- 108 6; unfavourable clinical outcome, using either the t-test or the Mann-Whitney-U test (M-W
- test), as appropriate, to compared variables between groups. We also developed and analysed
- a binomial logistic regression model to predict favourable or unfavourable clinical outcomes.

- P-values of <0.05 were considered statistically significant. IBM SPSS version 25 (Chicago,
- 112 IL, USA) was used for data analysis.

#### 113 **Results**

114

#### **Patient characteristics**

- Fifty-nine elderly patients aged over 80 years met the inclusion criteria and were treated
- between October 2015 and October 2021.
- The median age was 85 years (IQR 83-87) and 61.02% (27/59) were female. The median pre-
- morbid mRS was 0 (IQR0-1), but the mean value was 0.559.
- 119 Patients were admitted to hospital with a median NIHSS score of 24 (IQR 18-27), a median
- baseline ASPECTS score of 9 (IQR 7-9), and a median baseline DWI-ASPECTS score of 7
- 121 (IQR 6-8). Six patients were unable to undergo MRI due to metallic implants in their body.
- The most common cardiovascular risk factors (Table 1.) were hypertension (83.1%, 49/59),
- diabetes mellitus (20%, 12/59), hyper lipidemia (13.6%, 8/59) and arterial fibrillation
- 124 (56%,33/59). There is no statistically significant difference in cardiovascular risk factors
- between the favourable and unfavourable clinical outcome groups by t-test and M-W test
- 126 (p=0.7802 and p=0.7728). The most common site of occlusion (Table 2.) was the middle
- cerebral artery (MCA), particularly the M1 segment (28.9%,17/59): other site in the anterior
- circulation included the internal carotid artery (ICA) (22%, 13/59), the MCA M2 segment
- 129 (18.6%,11/59), the cervical segment of ICA (6.8%, 4/59), and the intracranial segment of ICA
- 130 (5%, 3/59). There is no statistically significant difference in the site of occlusion between the
- favourable and unfavourable clinical outcome groups by t-test and M-W test (p=0.8129 and
- 132 p=0.7481).
- More than half patients (61.02%,36/59) underwent intravenous thrombolysis prior to MT.
- Base-line characteristics at admission were compared between favourable clinical outcome
- (mRS  $\leq$ 3) and unfavourable clinical outcome (mRS >3) at 90days after admission. (table 3.)
- 136 In terms of age, the median age in the favourable clinical outcome group was 84 years (IQR
- 137 82.75-86), while the median age in the unfavourable clinical outcome group was 86 years
- (IQR 83-90), a statistically significant difference found by t-test (p=0.0319) (Table.3). In
- terms of time from onset to arrival, the median time in the favourable clinical outcome group

- was 52 minutes (IQR 38.75-165.75) and the median time in the unfavourable clinical outcome
- group was 57 minutes (IQR 39.5-157), with no statistically significant difference by t-test and
- M-W test (p=0.186 and p=0.9214) (Table.3). The median NIHSS score on admission was 20
- (IQR 16-24.25) in the favourable clinical outcome group and 26 (IQR 22.5-30) in the
- unfavourable clinical outcome group, a statistically significant difference was found by both t-
- test and M-W test (p=0.0005 and p=0.0008) (Table.3). For ASPECTS and DWI-ASPECTS on
- admission, the median ASPECTS in the favourable clinical outcome group was 9 (IQR 7-
- 9.25) and the median DWI-ASPECTS was 7.5 (IQR 6-9), whereas in the unfavourable
- clinical outcome group the median ASPECTS was 9 (IQR 7-9) and the median DWI-
- ASPECTS was 8 (IQR 6-8), and there was no statistically significant difference in either
- group by t-test and M-W test (p=0.0962 and p=0.2867, and p=0.3511 and p=0.587) (Table.3).
- For the NT-proBNP level (pg/ml) on admission, the median for the favourable clinical
- outcome group was 636.65 (pg/ml) (IQR 314.2-913), while the median for the unfavourable
- clinical outcome group was 1195.5 (pg/ml) (IQR 746.6-1814), a statistically significant
- difference was found by M-W test (p=0.0403) (Table.3). For admission D-dimer level ( $\mu$ g
- /ml), the median for the favourable clinical outcome group was 1.25 (µg/ml) (IQR 1.2-4.05),
- while the median for the unfavourable clinical outcome group was 2 (µg/ml) (IQR 0.875-1.8),
- a statistically significant difference was found by M-W test (p=0.0104) (Table.3). On the
- other hand, the median HbA1c level (%) on admission was 5.9 (%) (IQR 5.5-6) in the
- favourable clinical outcome group and 6 (%) (IQR 5.625-6.475) in the unfavourable clinical
- outcome group, which was not statistically significant by t-test and M-W test (p=0.2431 and
- 161 p=0.211) (Table.3).

167

- In binomial logistic regression analysis with further investigation, only a lower NIHSS score
- on admission was significantly correlated with a good clinical outcome (p=0.010).
- Although no significant correlations were found, there was a trend for favourable clinical
- outcome to correlate with younger age; NT-proBNP showed a slight tendency to correlate
- with favourable outcome (Table.4).

#### **Procedural and functional outcomes**

- These favorable clinical outcomes (mRS  $\leq$ 3) were observed in 47.5% (28/59) of patients at
- 90-days after admission. Post-interventional in-hospital mortality was 20.3% (12/59).

- Successful angiographic recanalization (mTICI ≥2b) was achieved in 74.6% (44/59) of
- patients. In contrast, unsuccessful recanalization (mTICI 0) occurred in four cases (6.8%).
- The percentage of good recanalization with mTICI 2b or better was 92.9% (26/28) in the
- favourable clinical outcome group and 58.1% (18/31) in the unfavourable clinical outcome
- group, a statistically significant differences was found in both t-test and M-W test (p=0.0018
- and p=0.0025) (Table.3).
- For the number of attempts, the median for the favourable clinical outcome group was 1(IQR
- 177 1-2) and the median for the unfavourable clinical outcome group was 2(IQR 1-2), a
- statistically significant differences was found in both t-test and M-W test (p=0.0225 and
- p=0.0244) (Table.3). For arrival to recanalization time (min), the median for the favourable
- clinical outcome group was 145 (min) (IQR 110.75-178.25), and the median for the
- unfavourable clinical outcome group was 140 (min) (IQR 117-177), which was not
- statistically significant by t-test and M-W test (p=0.4178 and p=0.8064) (Table.3). For
- puncture to recanalization time (min), or procedure time, the median for the favourable
- clinical outcome group was 41 (min) (IQR 21.5-57.25), and the median for the unfavourable
- clinical outcome group was 53 (min) (IQR 36-72), which was not a statistically significant
- difference by t-test and M-W test (p=0.2049 and p=0.054) (Table.3).
- 187 Binomial logistic regression analysis showed no significant correlations, but there was a trend
- for cases with TICI ≥2b and fewer attempts to correlate with favourable clinical outcomes
- 189 (Table.4).

190

# Discussion/Conclusion

- 191 In this study, in patients over 80 years of age undergoing MT for LVO, the factors associated
- with a favourable clinical outcome on t-test and M-W test were younger age, lower NIHSS
- score on admission, lower level of NT-proBNP on admission, lower level of D-dimer on
- admission, FPE (first pass effect) and good recanalisation, However, binomial logistic
- regression analysis showed that only a lower NIHSS score on admission was significantly
- associated with a favourable clinical outcome. For the other factors, only a trend was
- 197 associated with a favourable clinical outcome.
- Based on the hypothesis that many of the younger patients included in many reports of MT
- outcomes in LVO, including HERMES, had a pre-stroke mRS of 0 [1],

200	If moving from an mRS of 0 to 2 is considered a favourable clinical outcome, the mean pre-
201	stroke mRS of our study group, consisting of patients over 80 years of age, was 0.559, which
202	is consistent with moving from an mRS of 0 to 3, and we defined an mRS of 0-3 as a
203	favourable clinical outcome.
204	Age
205	In this study, although there were statistically significant differences in t-test, binomial
206	logistic regression analysis showed no significant differences, although it is clear that the
207	older the patient, the unfavourable clinical outcome. Similar findings have been reported
208	previously. [19,20,21] As previously noted, pre-existing physical and/or cognitive disability
209	and the high incidence of complications during hospitalization were thought to limit the
210	potential for post-stroke rehabilitation with increasing age. [16]
211	In this study of elderly patients with mRS6, deaths from infectious complications such as
212	aspiration pneumonia were more common, and deaths from malignant oedema or
213	intraparenchymal haemorrhagic infarction due to stroke were very rare. In the background,
214	many elderly patients have complications such as frailty, and it is thought that their sputum
215	expectoration and other functions are also declining, so it is necessary to pay attention to
216	infectious complications, especially aspiration pneumonia.
217	In older patients, atherosclerotic changes in the access route are often significant, and
218	treatment may be discontinued due to access difficulties. If such good recanalization is not
219	achieved, a good clinical outcome is unlikely. [12]
220	NIHSS score on admission
221	In this study, the only factors that were found to be significantly associated between lower
222	NIHSS scores on admission and favourable clinical outcomes were found not only in the t-test
223	and M-W test, but also in binomial logistic regression analysis. Similar findings have been
224	reported previously. [12,22]
225	Higher NIHSS scores reflect a more extensive cerebral ischaemic state and may indicate
226	ischaemic symptoms due to more proximal occluded arteries; Arsava et al. have noted the
227	presence of poor collateral circulation [23].

**D-dimer** 

In this study, there was a statistically significant difference between a high level of D-dimer 229 230 and an unfavorable clinical outcome in M-W test, but not in binomial logistic regression 231 analysis. D-dimer is a degradation product of cross-linked fibrin and a biomarker of the 232 fibrinolytic and coagulation system. [24] Elevated D-dimer levels in acute ischemic stroke have been associated with functional prognosis, acute morbidity, and infarct size. 233 234 [25,26,27,28] Hisamitsu et al. described that in patients with acute stroke, elevated D-dimer levels may be 235 236 related to increased activation of the fibrinolytic system in the thrombus of the occluded artery, and the larger the thrombus, the greater the increase. [29] Furthermore, they 237 238 speculated that a high D-dimer level leads to an unfavourable clinical outcome because the 239 amount of thrombus in the occluded artery is high, making it difficult to achieve a first pass 240 effect (FPE), resulting in distal embolization and prolonged procedure time. 241 NT-ProBNP 242 BNP is mainly synthesized cardiomyocytes in response to increased cardiac chamber wall 243 stress. [30] Activation of BNP produces an inactive NT-proBNP(N-terminal pro-brain 244 natriuretic peptide). [31] NT-proBNP has a longer half-life than BNP and results in less 245 fluctuation, but has been reported to be associated with adverse clinical outcomes. [32,33,34] 246 Plasma NT-proBNP levels have been reported to be elevated in patients with heart failure, left 247 ventricular dysfunction, acute coronary syndromes, and cardiogenic stroke.[35,36] In 248 addition, NT-pro BNP is a biological marker of cerebrovascular disease for identifying 249 ischemic stroke subtypes, and predicting the incidence of arterial fibrillation related stroke. 250 [37,38] In this study, almost all patients with elevated plasma NT-proBNP had a cardiogenic 251 embolism. Furthermore, there is increasing evidence that serum levels of NT-proBNP are 252 associated with an increasing risk of adverse clinical outcome in patients after stroke. [33,39] 253 There are no reports on the association between NT-proBNP and prognosis in MT for LVO in 254 the elderly patients. Chronic heart failure has been reported to exacerbate cerebrovascular 255 disease, dementia, and pneumonia and to reduce cardiac activity. [40,41,42] In this study, although there were statistically significant differences in the association of FPE 256 257 with favourable clinical outcomes in both t-test and M-W tests, there were no significant differences in binomial logistic regression analysis. The results suggesting that cardiac 258

259 function also contributes to improved prognosis after rehabilitation. Therefore, cardiac 260 function may be an indicator of functional prognosis after MT for LVO. 261 In this study, NT-proBNP levels were elevated well above 150 ng/ml, which is considered a 262 marker for heart failure. However, most patients had no obvious symptoms of heart failure. 263 In a case-cohort study from the REGARDS cohort, the authors confirmed that the association 264 of NT-proBNP with stroke was stronger for cardioembolic stroke. [43] 265 Zhang et al. proposed that three possible mechanisms of NT-pro BNP elevation; (1) central blood vessels damage promotes massive release of NT-proBNP from the CNS 266 to the blood, resulting in an absolute increase of NT-proBNP, (2) NT-proBNP 267 268 concentrations derived from the same precursor protein increase simultaneously 269 when cerebral infarction occurs; however, because of their different patterns of 270 metabolism, the activation of the endocrine system controlled by CNS degrade BNP more than NT-proBNP, resulting in a relative increase of NT-proBNP, (3) 271 272 following the deterioration that occurs due to heart failure, organisms begin to mobilize 273 activity factors that collaborate with the rennin-angiotensin-aldosterone system to 274 induce a diastolic state in blood vessels. [44] 275 In this study, the mechanism of NT-proBNP level elevation in LVO is not only one of the above three possibilities, but also the result of a sudden increase in blood pressure to 276 277 promote spontaneous recanalization of the main artery occlusion, which may have resulted in an excessive cardiac load. 278 279 The cases with elevated level of NT-proBNP and unfavorable clinical outcome included those 280 who died due to complications such as heart failure or aspiration pneumonia during the course 281 of hospitalization. Some cases were already complicated by aspiration pneumonia at the onset 282 of hospitalization, which may have played a role in the elevated NT-proBNP levels. 283 Many of the cases with elevated level of NTproBNP are consequently older with higher NIHSS, suggesting that more severe and more extensive fast running has occurred since then, 284 285 and the elevation may be the result of greater sympathetic activation

In the present study, the regression analysis failed to produce significant results due to insufficient power of number. Therefore, if n is increased, the regression model may be able to produce results showing that NPproBNP is an independent predictor of prognosis.

**FPE** 

In this study, although there were statistically significant differences in both t-test and M-W test, binomial logistic regression analysis showed no significant differences. Zaidat et al. showed that patients with mTICI 3 had better clinical outcome, lower mortality and fewer procedural adverse events after one pass.[45] Rousiers ED et al. described that FPE is a significant determinant of good clinical outcome in the oldest patients. Similar effects were observed in our results. [18] FPE has been shown to reduce procedure time, ischemic core volume expansion, and the incidence of procedural complications. [46,47] However, our results on puncture to recanalization time showed no correlation with clinical outcome.

#### Limitations

Nevertheless, the present study has some limitations. The study design is retrospective and non-randomized with a small sample size treated at a single institution. We did not compare patients treated with MT with those treated medical treatment including thrombolysis alone. We did not perform serial measurement of NT-proBNP levels and D-dimer levels; therefore, we were unable to examine the association of changes in these levels during after acute stroke phase. In the future, patient data should be accumulated and a large-scale prospective study should be conducted. Although the regression analysis could not produce significant results due to the insufficient power of the number, a certain trend can be observed, so if the number is increased in the future, it may be possible to produce results of an independent prognostic predictor in a regression model.

# Conclusion

The study found that factors associated with favourable clinical outcomes in patients aged 80 years or older undergoing MT for LVO were younger age, lower NIHSS score on admission, lower level of NT-proBNP on admission, lower level of D-dimer on admission,

FPE, and better recanalisation, with a strong correlated with lower NIHSS on admission, but a trend was observed for other factors. There are no reports on the correlation between NT-proBNP levels on admission and favourable clinical outcomes in MT for LVO in the elderly, and further verification is needed.

320	Acknowledgments
321 322	The medical assistants at Juntendo Nerima Hospital, Miyuki Yanagi and YokoTanaka, are thanked for their cooperation in data collection
323	Statement of Ethics
324 325 326	This retrospective single-center study, the protocol was approved by the Ethics Review Board at Juntendo University Nerima Hospital (18-39).
327	Conflict of Interest Statement
328	The authors have no conflicts of interest to declare.
329	Funding Sources
330	This work was supported by JSPS KAKENHI (Grant Numbers 21K18443).
331	<b>Author Contributions</b>
332 333 334 335	Takashi Mitsuhashihad full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Takashi Mitsuhashi, Kohsuke Teranishi, Joji Tokugawa, Makoto Hishii, and Hidenori Oishi. Acquisition of data: Takashi Mitsuhashi. Drafting of the manuscript: Takashi Mitsuhashi, Joji
<ul><li>336</li><li>337</li><li>338</li></ul>	Tokugawa, and Takumi Mitsuhashi. Critical revision of the manuscript for important intellectual content: Kohsuke Teranishi and Hidenori Oishi. Obtained funding: Takashi Mitsuhashi and Joji Tokugawa.
339	Data Availability Statement
340 341 342	The data that support the findings of this study are not publicity available due to their containing information that could compromise the privacy of research participants but are available from the corresponding author upon reasonable request.

#### Referrences

- Goyal M, Menon BK, van Zwam WH, Dippel DWJ, Mtchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischemic stroke: a meta-analysis of individual patient data from five randomized trials. Lancet. 2016;387(10029):1723-1731, https://doi.org/10.1016/S0140-6736(16)00163-X.
- Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for health care professional from the American Heart Association/American Stroke Association. Stroke. 2019;50:e344-e418, https://doi.org/10.1161/STR.00000000000000211.
- Yamagami H, Hayakawa M, Inoue M, Iihara K, Ogasawara K, Toyoda K, et al. Guidelines for mechanical thrombectomy in Japan, the fourth edition, March 2020: a guideline from the Japan Stroke Society, the Japan Neurosurgical society, and the Japanese Society for Neruoendovascular Therapy. Neurol Med Chir (Tokyo). 2021;61(3):163-92, <a href="https://doi.org/10.2176/nmc.nmc.st.2020-0357">https://doi.org/10.2176/nmc.nmc.st.2020-0357</a>.
- Hendrix P, Killer-Oberpfalzer M, Broussalis E, Melamed I, Sharma V, Mutzenbach S, et al. Outcome following mechanical thrombectomy for anterior circulation large vessel occlusion stroke in the elderly. Clin Neuroradiol. 2022;32(2):369-374, https://doi.org/10.1007/s00062-021-01063-9.
- 6. Alawieh A, Starke R, Chatterjee AR, Turk A, De Leacy R, Rai AT, et al. Outcomes of endovascular thrombectomy in the elderly: a' real-world multicenter study. J Neurointervent Surg. 2019;11(6):545-553, <a href="http://dx.doi.org/10.1136/neurintsurg-2018-014289">http://dx.doi.org/10.1136/neurintsurg-2018-014289</a>.
- 7. Duffis EJ, He W, Prestigiacomo CJ, Gandhi CD. Endovascular treatment for acute ischemic stroke in octogenarians compared with younger patients: a meta-analysis. Int J Stroke. 2014;9(3):308-12. https://doi.org/10.1111/ijs.12098.
- 8. Zeevi N, Kuchel GA, Lee NS, Staff I, McCullough LD. Interventional stroke therapies in the elderly: are we helping? AJNR Am J Neuroradiol. 2012;33(4):638-42, https://doi.org/10.3174/ajnr.A2845.
- Meyer L, Alexandrou M, Flottmann F, Deb-Chatterji M, Abdullayev N, Maus V, et al. Enbdovascular treatment of very elderly patients aged ≥90 with acute ischemic stroke. J Am Heart Assoc. 2020;9(5):e014447, <a href="https://doi.org/10.1161/JAHA.119.014447">https://doi.org/10.1161/JAHA.119.014447</a>

- 10. Rousiers ED, Lucas L, Richard S, Consoli A, Mazighi M, Labreuche J, et al. Impact of reperfusion for nonagenarians treated by mechanical thrombectomy insights from the ETIS registry. Stroke. 2019;50(11):3164-3169, https://doi.org/10.1161/STROKEAHA.119.026448.
- 11. Imahori T, Tanaka K, Arai A, Shiomi R, Fujiwara D, Mori T, et al. Mechanical thrombectomy for acute ischemic stroke patients aged 80 years or older. J Stroke Cerebrovasc Dis. 2017; 26(12):2793-2799, <a href="https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.06.060">https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.06.060</a>.
- 12. Barral M, Lassalle L, Dargazanli C, Mazighi M, Redjem H, Blanc R, et al. Predictors of favorable outcome after mechanical thrombectomy for anterior circulation acute ischemic in octogenarians. J of Neuroradiol. 2018;45(4):211-216, https://doi.org/10.1016/j.neurad.2018.01.055.
- 13. Derex L, Haesebaert J, Odier C, Alesefir W, Berthezene Y, Buisson M, et al. Predicotrs of outcome after mechanical thrombectomy in stroke patients aged 85 years. Canadian J of Neurol sci. 2022;49(1):49-54, https://doi.org/10.1017/cjn.2021.37.
- 14. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke.2019;50(12):e344-418. https://doi.org/10.1161/STR.00000000000000011.
- 15. Zaidat OO, Castonguay AC, Nogueira RG, Haussen DC, English JD, Satti SR, et al. TREVO stent-retriever mechanical thrombectomy for acute ischemic stroke secondary to large vessel occlusion registry. J Neurointerv Surg. 2018;10(6):516-524, <a href="http://dx.doi.org/10.1136/neurintsurg-2017-013328">http://dx.doi.org/10.1136/neurintsurg-2017-013328</a>.
- Meyer L, Alexandrou M, Leischner H, Flottmann F, Deb-Chatterji M, Abdullayev N, et al. Mechanical thrombectomy in nonagenarians with acute ischemic stroke. J Neurointervent Surg. 2019;11(11):1091-1094, <a href="http://dx.doi.org/10.1136/neurintsurg-2019-014785">http://dx.doi.org/10.1136/neurintsurg-2019-014785</a>.
- 17. Wilson JTL, Hareendran A, Hendry A, Potter J, Bone I, Muir KW. Reliability of the modified Rankin Scale across multiple raters: benefits of a structured interview. Stroke. 2005;36(4):777-781, https://doi.org/10.1161/01.STR.0000157596.13234.95.
- 18. Rangaraju S, Haussen D, Nogueira RG, Nahab F, Frankel M. Comparison of 3-month stroke disability and quality of life across modified Rankin Scale categories. Intervet Neurol. 2017;6(1-2):36-41, https://doi.org/10.1159/000452634.
- 19. Hussein HM, Georgiadis AL, Vazquez G, Miley JT, Memon MZ, Mohammad YM, et al. Occurrence and predictors of futile recanalization following endovascular treatment among patients with acute ischemic stroke: a multicenter study. AJNR Am J Neuroradiol. 2010;31(3):454-8, https://doi.org/10.3174/ajnr.A2006.
- 20. Singer OC, Haring HP, Trenkler J, Nolte CH, Bohner G, Reich A, et al. Age dependency of successful recanalization in anterior circulation stroke: the ENDOSTROKE study. Cerebrovasc

- Dis. 2013;36(5-6):437-45, https://doi.org/10.1159/000356213.
- 21. Nogueira RG, Liebeskind DS, Sung G, Duckwiler G, Smith WS, MERCI; Multi MERCI writing Committee. Predictors of good clinical outcomes, mortality, and successful revascularization in patients with acute ischemic stroke undergoing thrombectomy: pooled analysis of the mechanical embolus removal in cerebral ischemia (MERCI) and multi MERCI trials. Stroke. 2009; 40(12):3777-83, https://doi.org/10.1161/STROKEAHA.109.561431.
- 22. Kurre W, Aguilar-Perez M, Niehaus L, Fischer S, Schimid E, Bazner H, et al. Predictors of outcome after mechanical thrombectomy for anterior circulation large vessel occlusion in patients aged ≥80 years. Cerebrovasc Dis. 2013;36(5-6):430-6, https://doi.org/10.1159/000356186.
- 23. Arsava EM, Vural A, Akpinar E, Gocmen R, Akcalar S, Oguz KK, et al. The detrimental effect of aging on leptomeningeal collaterals in ischemic stroke. J Stroke Cerebrovasc Dis. 2014; 23(3):421-6, <a href="https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.03.014">https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.03.014</a>.
- 24. Goldenberg NA, Jenkins S, Jack J, Armstrong-Wells J, Fenton LZ, Stence NV, et al. D-dimer, and risk of poor neurologic outcome in childhood-onset arterial ischemic stroke. J Pediatr. 2013;162(5):1041-6.e1, <a href="https://doi.org/10.1016/j.jpeds.2012.11.035">https://doi.org/10.1016/j.jpeds.2012.11.035</a>.
- 25. Dougu N, Takashima S, Sasahara E, Taguchi Y, Toyoda S, Hirai T, et al. Predictors of poor outcome in patients with acute cerebral infarction. J Clin Neurol. 2011;7(4):197-202, https://doi.org/10.3988/jcn.2011.7.4.197.
- 26. Wang J, Ning R, Wang Y. Plasma D-dimer level, the promising prognostic biomarker for the acute cerebral infarction patients. J Stroke Cerebrovasc Dis. 2016;25(8):2011-5, https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.12.031.
- 27. Hasan N, McColgan P, Bentley P, Edwards RJ, Sharma P. Towards the identification of blood biomarker for acute stroke in humans: a comprehensive systematic review. Br J Clin Pharmacol. 2012;74(2):230-240, <a href="https://doi.org/10.1111/j.1365-2125.2012.04212.x.">https://doi.org/10.1111/j.1365-2125.2012.04212.x.</a>
- 28. Matsumoto M, Sakaguchi M, Okazaki S, Furukado S, Tagaya M, Etani H, et al. Relationship between plasma (D)-dimer level and cerebral infarction volume in patients with non-valvular arterial fibrillation. Cerebrovasc Dis. 2013;35(1):64-72, <a href="https://doi.org/10.1159/000345336">https://doi.org/10.1159/000345336</a>.
- 29. Hisamitsu Y, Kudo T, Fudaba H, Sugita K, Fujiki M, Ide S, et al. High D-dimer concentration is a significant independent prognostic factor in patients with acute large vessel occlusion undergoing endovascular thrombectomy. World Neurosurg. 2022;160:e487-e493, https://doi.org/10.1016/j.wneu.2022.01.052.
- 30. Richards AM. N-terminal B-type natriuretic peptide in heart failure. Heart Fail Clin. 2018;14(1):27-39, <a href="https://doi.org/10.1016/j.hfc.2017.08.004">https://doi.org/10.1016/j.hfc.2017.08.004</a>.
- 31. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Eng J Med. 1998; 339(5):321-8.
- 32. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Caridiol. 2007;50(25):2357-2368, <a href="https://doi.org/10.1016/j.jacc.2007.09.021">https://doi.org/10.1016/j.jacc.2007.09.021</a>.

- 33. Yip HK, Sun CK, Chang LT, Chen MC, Liou CW. Time course and prognostic value of plasma levels of N-terminal pro-brain natriuretic peptide in patients after ischemic stroke. Circ J. 2006;70(4):447-52, <a href="https://doi.org/10.1253/circj.70.447">https://doi.org/10.1253/circj.70.447</a>.
- 34. Idris I. Hill R, Ross I, Sharma JC. N-terminal pro-brain natriuretic peptide predicts 1-year mortality following acute stroke: possible evidence of occult cardiac dysfunction among patients with acute stroke. Age Ageing. 2010;39(6):752-5, <a href="https://doi.org/10.1093/ageing/afq098">https://doi.org/10.1093/ageing/afq098</a>.
- 35. Castelnuovo AD, Veronesi G, Costanzo S, Zeller T, Schnabel RB, de Curtis A, et al. NT-proBNP (N-terminal pro-B-type natriuretic peptide) and the risk of stroke. Stroke. 2019;50(3):610-617, https://www.ahajournals.org/doi/10.1161/STROKEAHA.118.023218
- 36. Iltumur K, Yavavli A, Apak I, Ariturk Z, Toprak N. Elevated plasma N-terminal pro-brain natriuretic peptide levels in acute ischemic stroke. Am Heart J. 2006;151(5):1115-22, https://doi.org/10.1016/j.ahj.2005.05.022.
- 37. Zecca B, Mandelli C, Maino A, Casiraghi C, Bolla G, Consonni D, et al. A bioclinical pattern for the early diagnosis of cardioembolic stroke. Emerg Med Int. 2014;2014: 242171, <a href="https://doi.org/10.1155/2014/242171">https://doi.org/10.1155/2014/242171</a>.
- 38. Nakamura M, Ishibashi Y, Tanaka F, Omama S, Onoda T, Takahashi T, et al. Ability of B-Type Natriuretic Peptide Testing to Predict cardioembolic stroke in the general population comparison with c-reactive protein and urinary albumin. Circ J. 2018;82(4):1017-1025, <a href="https://doi.org/10.1253/circj.CJ-17-1124">https://doi.org/10.1253/circj.CJ-17-1124</a>.
- 39. Garcia-Berrocoso T, Giralt D, Bustamante A, Etgen T, Jensen JK, Sharma JC, et al. B-type natriuretic peptides and mortality after stroke. a systematic review and meta-analysis. Neurology. 2013;81(23):1976-85, https://doi.org/10.1212/01.wnl.0000436937.32410.32.
- 40. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991;121(3 Pt 1):951-7, https://doi.org/10.1016/0002-8703(91)90225-7.
- 41. Pasini E, Aquilani R, Testa C, Baiardi P, Angioletti S, Boschi F, et al. Pathogenic gut flora in patients with chronic heart failure. JACC Heart Fail. 2016;4(3):220-227, <a href="https://doi.org/10.1016/j.jchf.2015.10.009">https://doi.org/10.1016/j.jchf.2015.10.009</a>.
- 42. Haeusler KG, Laufs U, Endres M. Chronic heart failure and ischemic stroke. Stroke. 2011;42(10):2977-82, https://doi.org/10.1161/STROKEAHA.111.628479.
- 43. Cushman M, Judd SE, Howard VJ, Kissela B, Gutierrez OM, Jenny NS, et al. N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort. Stroke. 2014;45(6):1646-1650, <a href="https://doi.org/10.1161/STROKEAHA.114.004712">https://doi.org/10.1161/STROKEAHA.114.004712</a>.
- 44. Zhang X, Wang W, Yu Y, Wang Q, Yang Y, Wen D, et al. BNP and NT-proBNP assyas for heart-failure diagnosis inpatients with cerebral infarction. Lab Medicine 2013;44(1):46-50, https://doi.org/10.1309/LMPEAZF6UYU8FG4H.
- 45. Zaidat OO, Castonguay A, Linfante I, Gupta R, Martin CO, Holloway WE, et al. First pass effect:

- A new measure for stroke thrombectomy devices. Stroke. 2018;49(3):660-666, https://doi.org/10.1161/STROKEAHA.117.020315.
- 46. Meretoja A, Keshtkaran M, Tatilisumal T, Donnan GA, Churilov L. Endovascular therapy for ischemic stroke: save a minute-save a week. Neurology. 2017;88(22):2123-2127, https://doi.org/10.1212/WNL.000000000003981.
- 47. Hassan AE, Shariff U, Saver J, Goyal M, Liebeskind D, Jahan R, et al. Impact of procedural time on clinical and angiographic outcomes in patients with acute ischemic stroke receiving endovascular treatment. J NeuroInterv Surg. 2019;11(10):984-988, http://dx.doi.org/10.1136/neurintsurg-2018-014576.

# **Figure Legends**

Table 1. Patients' characteristics.

Table 2. Occlusion site.

Table 3. Prognostic factor analysis.

Table 4. Binomial logistic regression model analysis for prognostic factor.

	Favourable clinical outcome 28 cases	Unfavourable clinical outcome 31 cases	
Hypertension	14 (50%)	25 (80.65%)	
Diabetes	4 (14.29%)	8 (25.81%)	
Hyperlipidemia	5 (17.86%)	3 (9.68%)	
Atrial fibrillation	24 (85.71%)	19 (61.29%)	

t-test and M-W test (p=0.7802 and p=0.7728)

Table 1.
Patients' characteristics

	Favourable clinical outcome 28 cases	Unfavourable clinical outcome 31 cases
Cervical ICA	0	4
Intracranial ICA	1	2
Terimnal ICA	6	7
M1 proximal	6	3
M1 distal	8	10
M2/M3	7	4
Tandem	0	1

t-test and M-W test (p=0.8129 and p=0.7481)

Table 2. Occlusion site

ICA: internal carotid artery, M1:middle cerebral artery horizontal segment, M2/M3: middle cerebral artery insular segment/ opercular segment, tandem: sub-occlusion or stenosis of extracranial internal carotid artery, together with simultaneous intracranial large vessel occlusion.

	Favorable clinical outcome 28cases	Unfavorable clinical outcome 31 cases	t-stats	p M-V	V test	p
age, median (IQR) years	84 (82.75-86)	85 (83-90)	-2.1998	0.03189 *	329	0.1107
female	11(39.29%)	16(51.6%)				
CT ASPECTS, median (IQR)	9 (7-9.25)	9 (7-9)	-3.6873	0.0962	502.5	0.2867
MRI DWI-ASPECTS, median (IQR)	7.5 (6-9)	8 (6-8)	1.9157	0.3511	381.5	0.587
NIHSS, median (IQR)	20 (16-24.25)	26 (22.5-30)	-3.6873	0.00051 *	213	0.0008 *
intravenous thrombolysis	18 (64.29%)	18 (58.06%)				
HbA1c (median, IQR) (%))	5.9(2.2-6)	6(5.625-6.475)	-1.180004	0.2431	326.5	0.211
D-dimer (median, IQR) (µg/ml)	1.25(0.875-1.8)	2(1.2-4.05)	-0.70065	1.4864	255	0.01037 *
NT-proBNP (median, IQR) (pg/ml)	636.65(314.2-913)	1195.5(746.6-1814)	-1.6016	0.1164	169	0.04028 *
TICI2b <	26 (92.86%)	18 (58.06%)	3.28524	0.00175 *	585	0.002457 *
number of passes, median (IQR)	1 (1-2)	2 (1-2)	2.34518	0.02252 *	562	0.024427 *
groin to recanlization time, median (IQR) (min)	41(21.5-57,25)	53(36-72)	-1.28237	0.20491	307	0.05475
arrival to recanalization time, median (IQR (min)	) 145(110.75-178.25)	148(117-177)	0.816	0.4178	-0.251	0.8064
onset to arrival time, median (IQR) (min)	52(38.75-165.75)	57(39.5-157)	1.3385	0.186023	441	0.9214

Table 3.

Prognosis factor analysis

CT ASPECTS: Alberta Stroke Early CT score, MRI DWI-ASPECTS: diffusion weighted imaging ASPECTS, NIHSS: National Institutes of Health Stroke Scale, HbA1c: Glycated hemoglobin, NT-proBNP: N-Terminal Pro-Brain Natriuretic Peptide, mTICI: modified Thrombolysis in Cerebral Infarction, t-test: Student's t-test, M-W test: Mann-Whitney U test, \*: statistically significant.

	В	Standard Error	Wald	p	Exp(B)
Age	-0.164	0.125	1.712	0.191	0.849
NIHSS score on admission	-0.183	0.076	5.749	0.017	0.833
NT-proBNP	-0.001	0,.000	1.678	0.195	0.999
D-dimer	-0.046	0.99	0.214	0.644	1.047
Number of passes	-0.541	0.578	0.876	0.349	0.582
mTICI ≥2b	2.694	1.377	3.825	0.050	14.788
Constant	16.626	11.065	2.258	0.133	16609785.569

Table 4. Binomial logistic regression model analysis for prognostic factor:

NIHSS: National Institutes of Health Stroke Scale, NT-proBNP: N-Terminal Pro-Brain Natriuretic Peptide, mTICI: modified Thrombolysis in Cerebral Infarction, \*: statistically significant.